• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    HEXO Reports Fourth Quarter and Fiscal Year 2021 Financial Results Highlighting Strong Growth

    10/29/21 7:22:41 AM ET
    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $HEXO alert in real time by email
    • Total net sales growth of 71% quarter-over-quarter and 43% from Q4'20, marking HEXO's best quarter of sales to date.
    • Total Q4'21 net revenue increased to $38.7 million from $22.6 million in Q3'21
    • Total net revenue for FY21 grew 53% to $123.5 million from $80.6 million in FY20.
    • Maintained leading market share position relative to peers as market continues to diversify.
    • Completed the acquisition of Zenabis Global Inc. ("Zenabis")           

    OTTAWA, Oct. 29, 2021 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") today reported its financial results for the fourth quarter ("Q4'21") and fiscal year ended July 31, 2021 ("F'21"). All amounts are expressed in Canadian dollars unless otherwise noted.

    "I am honoured and humbled to join the team as HEXO's President & CEO," said Scott Cooper. "I look forward to continuing to build on HEXO's strong foundation with an immediate priority of continuing to integrate our recent acquisitions and reviewing our financial position, with the ultimate goal of driving growth and profitability through the commercialization of cannabis consumer packaged goods products."

    "As we review our last fiscal year, I would like to highlight some key achievements.  Last fiscal, HEXO achieved its highest net revenue in the Company's history, leads the Canadian cannabis market in four categories and completed three acquisitions, including the transformative Redecan acquisition, propelling the Company to the number one market share position in Canadian adult-use recreational cannabis sales," commented Cooper.

    Business Update

    M&A

    Key Highlights to July 31, 2021

    • Closed the Zenabis acquisition on June 1, 2021, offering diversified cultivation facilities, including a state-of-the-art indoor grow facility in Atholville, NB.
    • Zenabis contributed $6.8 million in net revenue for the two months ended July 31, 2021.

    Subsequent Events

    • The Company completed the acquisitions of Redecan and 48North Cannabis Corp. ("48North"). Through the integration progress, HEXO is focused on ensuring that it implements the strengths of each acquired company across the organization, identifies and resolves any weaknesses, and obtains synergistic value for the overall organization.
    • HEXO believes these acquisitions will increase its market share, accelerate its path to profitability, and create accretive synergies.

    Operations

    Key Highlights to July 31, 2021

    • Committed to ESG leadership, by offsetting 100% of its 2020 operational carbon emissions and personal emissions for all employees1.  The Company also committed to offsetting the plastic used in its pouch packaging.

    Subsequent Events

    • The Company undertook a strategic reorganization, announcing the departure of its Co-Founder and CEO, Sebastien St-Louis and the appointment of Scott Cooper as HEXO's new President & CEO.
    • Scott joins HEXO from Truss Beverage Co., a joint venture between Molson-Coors Canada and HEXO which holds the number one market share in cannabis infused beverages in Canada, where he held the position of President & CEO. For a period of not more than six months, Scott will simultaneously remain in this role.
    • HEXO also announced the appointment of Valerie Malone as Chief Commercial Officer and Guillaume Jouet as Chief People & Culture Officer. Both executives bring significant consumer-packaged good experience to the organization.

    Canadian cannabis market

    Key Highlights to July 31, 2021

    • Net revenue increased 71% quarter-over-quarter and 43% from Q4'20, marking HEXO's highest quarter of revenue to date.
    • Total Q4'21 net revenue increased to $38.7 million from $22.6 million in Q3'21
    • Total net revenue for FY21 grew to $123.5 million from $80.6 million in FY20.
    • Increased market share in several Canadian provinces, including Ontario, Alberta and British Colombia, and maintained a top two market share in Quebec.
    • Adult-use net revenues, exclusive of beverages, increased 28% quarter-over-quarter.
    • Cannabis beverage net revenues increased 70% quarter-over-quarter and 161% from fiscal 2020.

    Maintained leading market position relative to peers as market share continues to diversify.

    HEXO USA

    Key Highlights to July 31, 2021

    • On June 28, 2021, HEXO announced the closing of the acquisition of a 50,000 sq. ft. facility in Colorado providing the Company with the necessary infrastructure to execute on its U.S. expansion plans. The facility is zoned for producing a full range of cannabis products and offers a variety of operational capabilities.             

    Subsequent Events

    • Truss CBD USA announced the expansion of Veryvell, a line of hemp-derived CBD and adaptogen beverages, to 17 states following a successful Colorado launch in 2020. Truss CBD USA is a joint venture by Molson Coors Beverage Company and HEXO USA Inc, a subsidiary of HEXO poised to capture the US cannabis infused beverage market.

    Financial Update

    In 000'sFor the three months endedFor the twelve months ended

      Income Statement SnapshotJuly 31,

     2021
     April 30,

     2021
     July 31,

    2020 
     July 31,

     2021
     July 31,

     2020
     
                       $                 $ $ $ $ 
    Revenue from sale of goods53,022 33,082 36,140 173,081 110,149 
    Excise taxes(14,365)(10,482)(9,082)(49,583)(29,598)
    Net revenue from sale of goods38,657 22,600 27,058 123,498 80,551 
    Ancillary revenue103 60 87 271 233 
    Total revenue38,760 22,660 27,145 123,769 80,784 
               
    Gross profit before adjustments27,988 5,006 8,104 34,175 26,953 
    Gross profit/(loss) before fair value adjustments1,499 4,379 (36,012)29,066 (46,421)
    Gross profit/(loss)23,234 8,816 (34,690)48,798 (57,975)
               
    Operating expenses(63,116)(24,906)(71,509)(134,293)(418,576)
    Loss from operations(59,882)(16,090)(106,199)(85,495)(476,551)
    Other expenses and losses(9,630)(4,621)(63,333)(29,664)(75,961)
    Loss and comprehensive loss before tax(69,512)(20,711)(169,532)(115,159)(552,512)
               
    Current and deferred tax recovery397 – – 397 6,023 
    Other comprehensive income1,156 3 – 1,152 – 
    Total Net loss and comprehensive loss(67,959)(20,708)(169,532)(113,610)(546,489)



    1The Company has adjusted the presentation of gross profit before fair value adjustments by removing inventory and biological asset write offs and impairment losses.
    2See section ‘Cost of Sales, Excise Taxes and Fair Value Adjustments' for reconciliation of gross profits

    Operating Expenses

    In 000'sFor the three months ended

    For the years ended

     July 31,

    2021
    April 30,

    2021
     July 31,

    2020
     July 31,

    2021
    July 31,

    2020
     $$ $ $$
    Selling, general and administration119,16011,178 12,436 54,54352,793
    Marketing and promotion3,6652,452 2,375 10,34812,474
    Share-based compensation8272,715 4,373 11,73125,790
    Research and development934730 677 3,8354,639
    Depreciation of property, plant and equipment1,7281,612 1,179 6,0976,072
    Amortization of intangible assets1,002371 249 2,0503,939
    Restructuring costs1,562336 (79)3,2834,767
    Impairment of property, plant and equipment19,35016 46,414 20,23079,418
    Impairment of intangible assets–– 2,000 –108,189
    Impairment of goodwill–– – –111,877
    Realization of onerous contract–– 1,763 –4,763
    Disposal of long-lived assets–– 122 1,2943,855
    Loss/(gain) on disposal of property, plant and equipment19(19)– 64–
    Acquisition transaction costs14,8691,871 – 17,174–
    Health Canada Recovery Fee's1–3,644 – 3,644–
    Total63,11624,906 71,509 134,293418,576



    1The Company has adjusted the presentation of the Selling, General and Administrative expenses to breakdown the Health Canada Recovery Fee's for ease of user review and identification. This presentation differs from that of the Company's interim financial statement for the year ended July 31, 2021.  

    Other Matters

    Gross margins

    Quarter-over-quarter, the Company's total gross margin declined to 20% from 22% in Q3'21. Net adult-use revenue (exclusive of beverages) gross margin declined to 12% from 28% due to; increases to sales in higher excise tax burdened markets, decreases to average selling prices, and the crystallization of fair value adjustments upon the business acquisition of Zenabis.

    Normalizing for the impact of the crystallization, the Company's total gross margin would improve to 26% in Q4'21. Strong margined international sales grew significantly in period to net revenues of $6.8 million and a gross margin contribution of 65%. Wholesales were also impacted by the crystallization of fair value adjustments on the purchase price accounting of Zenabis, normalized for this, margins would otherwise have been 35% versus reported gross margin of (65%).

    Going Concern & the Senior Secured Convertible Note

    The Company acknowledges the ongoing concern with its senior secured convertible notes issued on May 27, 2021. The Company has maintained a positive relationship with the holder, with the holder having negotiated and agreed to two amendments favorable to the Company.  While there exists a risk that significant cash outflows may be required over the next twelve months under the terms of the Senior Secured Convertible Note, the Company has been working with the Holder to renegotiate the terms of the Senior Secured Convertible Note. 

    The Company has sufficient funding for ongoing working capital requirements, however, current funds on hand, combined with operational cash flows, are not sufficient to also support funding potential cash requirements under the Senior Secured Convertible Note, investments required to continue to develop cultivation and distribution infrastructure, and the future growth plans of the Company. Management is exploring several options to secure the necessary financing, which could include the issuance of new public or private equity or debt instruments, supplemented with operating cash inflows from operations.

    Nevertheless, there is risk that certain sources of additional future funding will not be available to the Company or will be available on terms which are acceptable to management. In the meantime, Management continues to monitor and manage its cash flow in relation to its strategic growth objectives and working capital requirements.

    Non-IFRS Measures

    In this press release, reference is made to gross profit before adjustment, profit/margin before fair value adjustments, adjusted gross profit/margin, adjusted EBITDA, and revenue per gram equivalent which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS, and are unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complementary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of a review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company's Management's Discussion and Analysis for the fiscal year ended July 31, 2021, filed under the Company's profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov respectively

    Conference Call

    The Company will hold a conference call, October 29, 2021 to discuss these results. Scott Cooper, President & CEO, and Trent MacDonald, CFO, will host the call starting at 8:30 a.m. Eastern. Analysts' question and answer period will follow management's presentation.

    Date: October 29, 2021

    Time: 8:30 a.m. ET

    Webcast: https://events.q4inc.com/attendee/987736433

    For previous quarterly results and recent press releases, see hexocorp.com.

    About HEXO Corp

    HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, Redecan, UP Cannabis, Namaste Original Stash, 48North, Trail Mix, Bake Sale, REUP and Latitude brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint venture with Molson-Coors. With the completion of HEXO's recent acquisitions of Redecan and 48North, HEXO is a leading cannabis products company in Canada by recreational market share. For more information, please visit www.HEXOcorp.com.

    Forward-Looking Statements

    This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include but are not limited to the Company's statements with respect to management's belief that certain expenses included in operating expenses are non-recurring and related to significant changes in market conditions and the refocus of its operations on becoming Adjusted EBITDA positive.

    A more complete discussion of the risks and uncertainties facing the Company appears in the Company's Annual Information Form and other continuous disclosure filings, which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

    Investor Relations:

    [email protected]

    www.hexocorp.com

    Media Relations:

    (819) 317-0526

    [email protected]

    1 Estimated personal emissions based on the average Canadian's emissions from heating and powering their homes, driving and food consumption.



    Primary Logo

    Get the next $HEXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HEXO

    DatePrice TargetRatingAnalyst
    3/4/2022$1.00 → $1.25Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022$1.20 → $0.90Neutral
    Cantor Fitzgerald
    1/27/2022$1.07 → $0.53Underperform → Hold
    Jefferies
    12/15/2021$2.00 → $0.80Neutral → Underperformer
    CIBC
    12/15/2021Neutral → Sector Underperform
    CIBC
    12/15/2021$2.10 → $1.20Neutral
    Cantor Fitzgerald
    10/29/2021$2.29 → $2.10Neutral
    Cantor Fitzgerald
    More analyst ratings

    $HEXO
    SEC Filings

    See more
    • SEC Form 15-12G filed by HEXO Corp.

      15-12G - HEXO Corp. (0001690947) (Filer)

      7/3/23 4:15:19 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 25-NSE filed by HEXO Corp.

      25-NSE - HEXO Corp. (0001690947) (Subject)

      6/22/23 5:20:40 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form F-10POS filed by HEXO Corp.

      F-10POS - HEXO Corp. (0001690947) (Filer)

      6/22/23 5:08:06 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HEXO Corp. (Amendment)

      SC 13G/A - HEXO Corp. (0001690947) (Subject)

      2/8/23 3:28:12 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed by HEXO Corp.

      SC 13G - HEXO Corp. (0001690947) (Subject)

      2/8/22 3:16:31 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G/A filed by HEXO Corp. (Amendment)

      SC 13G/A - HEXO Corp. (0001690947) (Subject)

      11/16/21 8:34:29 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HEXO Corp. Announces Completion of Acquisition by Way of Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today the closing of the second of two tranches of the non-brokered private placement of Series 1 Preferred Shares (the "Private Placement") previously announced on June 1, 2023 and the subsequent completion of the transactions contemplated by the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") involving the Company and Tilray Brands, Inc. ("Tilray"). "On behalf of HEXO's board and management team, I'd like to extend our deepest thanks to the entire HEXO team for their continued commitment to our business and customers," said Charlie Bow

      6/22/23 5:02:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Corp. Announces Receipt of Final Order for Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted the final order (the "Final Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement"), pursuant to which Tilray Brands, Inc. ("Tilray") will acquire all of the issued and outstanding common shares (the "Common Shares") and non-voting Series 1 Preferred Shares of the Company. Holders of Common Shares of the Company (the "Common Shareholders") will receive 0.4352 of a share of Tilray common stock (the "Tilray Shares") for each w

      6/19/23 4:06:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Reports Q3'23 Financial Results

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, today reported its financial results for the third quarter of the 2023 fiscal year ("Q3'23"). All currency amounts are stated in Canadian dollars unless otherwise noted. "In the third quarter, we entered into a definitive arrangement agreement whereby Tilray will acquire all outstanding shares of HEXO," said Charlie Bowman, President and Chief Executive Officer of HEXO. "We continue to expect the transaction will be completed by June 30, 2023." "HEXO recorded $21.6 million in net revenues in the third quarter, representing an 11% decline from the second quarter," noted Jul

      6/14/23 4:51:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HEXO upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded HEXO from Hold to Speculative Buy and set a new price target of $1.25 from $1.00 previously

      3/4/22 8:45:54 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO upgraded by Canaccord Genuity

      Canaccord Genuity upgraded HEXO from Hold to Speculative Buy

      3/4/22 7:41:12 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • Cantor Fitzgerald reiterated coverage on HEXO with a new price target

      Cantor Fitzgerald reiterated coverage of HEXO with a rating of Neutral and set a new price target of $0.90 from $1.20 previously

      3/4/22 6:18:18 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Leadership Updates

    Live Leadership Updates

    See more
    • HEXO Announces Election of Directors

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO"), a leading producer of high-quality cannabis products, today announced that at the annual general meeting of shareholders held on January 31, 2023 (the "Meeting"), each of the eight director nominees was elected as a director of HEXO. Detailed results of the vote are set out below. Nominee Votes For Votes Withheld Total Votes Cast Percentage of Votes For Percentage of Votes Withheld Mark Attanasio 2,063,211 434,874 2,498,058 82.592% 17.408% Vincent Chiara 1,983,425 514,662 2,498,087 79.398% 20.602% Denise Faltischek 2,072,889 425,198 2,498,087 82.979% 17.021% Hélène

      1/31/23 5:30:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Announces Leadership Transition; Company Appoints Charlie Bowman as Chief Executive Officer and Julius Ivancsits as Chief Financial Officer

      Scott Cooper Steps Down; Board of Directors Acknowledge Cooper in Stabilizing the Company Bowman and Ivancsits to Lead HEXO's Continued Transformation and Growth GATINEAU, Quebec, April 29, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO" or the "Company") (TSX:HEXO, NASDAQ:HEXO) today announced that Charlie Bowman has been appointed the Company's acting President and Chief Executive Officer, effective today. Mr. Bowman will move into a permanent role upon the successful completion of Health Canada's security clearance process for key personnel, which has been initiated. Concurrently, Scott Cooper is stepping down from his role as HEXO's President and Chief Executive Officer. "I am honoured t

      4/29/22 9:00:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Announces the Appointment of a New Board Member and Acting CFO

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 11, 2021 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021. GATINEAU, Quebec, Jan. 05, 2022 (GLOBE NEWSWIRE) -- HEXO Corp ("HEXO", or the "Company") (TSX:HEXO, NASDAQ:HEXO), today announced the appointment of William Todd Montour to the Company's Board of Directors following the resignation of Jason Ewart, effective immediately. "I am pleased to welcome Will to the Board, and I am confident that his experience in cannabis operations and commercialization will be invaluable to the Company as we enter our next stage of

      1/5/22 8:05:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care

    $HEXO
    Financials

    Live finance-specific insights

    See more
    • HEXO to Host Third Quarter 2023 Earnings Conference Call

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio-only conference call on Thursday, June 15, 2023, at 10 a.m. EDT, to review its financial results for the third fiscal quarter, ended April 30, 2023. The results will be released after market close on Wednesday, June 14, 2023. Following the prepared remarks, there will be a question-and-answer session. Ch

      6/12/23 5:10:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • Tilray Brands Reports Third Quarter Fiscal Year 2023 Financial Results and Announces Accretive Acquisition of 100% of HEXO Corp.

      Delivered $145.6 Million in Net Revenue and 16th Consecutive Quarter of Positive Adjusted EBITDA Maintained #1 Cannabis Market Share Position in Canada, the Largest Federally Legal Cannabis Market in the World; With HEXO Transaction, Poised to Substantially Increase Canadian Revenue Medical Cannabis Leader in Europe Achieved Key Efficiency Milestones on Accelerated Path to Positive Cash Flow, Company Reiterates Cash Flow Guidance LEAMINGTON, Ontario and NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) --  Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide commun

      4/10/23 4:15:00 PM ET
      $HEXO
      $TLRY
      Pharmaceuticals and Biotechnology
      Health Care
      Medicinal Chemicals and Botanical Products
    • HEXO to Host Second Quarter 2023 Earnings Conference Call

      This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 2, 2022 to its short form base shelf prospectus dated May 7, 2021 and amended and restated on May 25, 2021 HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, announced today that it will hold an audio only conference call on March 17, 2023, at 10 a.m. EDT, to review its financial results for the second fiscal quarter, ended January 31, 2023. The results will be released after market close on Thursday, March 16, 2023. Following the prepared remarks, there will be a question-and-answer session. Charlie Bo

      3/14/23 7:00:00 AM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care